Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.25.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Costs and expenses:        
Research and development $ 2,239 $ 85 $ 9,057
General and administrative 1,577 2,142 5,275 7,067
Total costs and expenses 1,577 4,381 5,360 16,124
Loss from operations (1,577) (4,381) (5,360) (16,124)
Change in fair value of warrant liability (3,161)
Gain on sale of assets, net 110
Other income/(expenses), net 45 106 (22) 306
Net loss (1,532) (4,275) (8,433) (15,818)
Deemed dividend relating to warrant exchange (618) (618)
Net loss attributable to common shareholders $ (2,150) $ (4,275) $ (9,051) $ (15,818)
Net loss per share - basic $ (0.40) $ (0.85) $ (1.74) $ (3.30)
Net loss per share - diluted $ (0.40) $ (0.85) $ (1.74) $ (3.30)
Weighted average common shares outstanding:        
Weighted average common shares outstanding - basic 5,435,829 5,037,829 5,204,544 4,791,572
Weighted average common shares outstanding - diluted 5,435,829 5,037,829 5,204,544 4,791,572
Other comprehensive gain, net of tax        
Unrealized gain on securities available-for-sale $ 51 $ 221
Other comprehensive gain, net of tax 51 221
Comprehensive loss $ (1,532) $ (4,224) $ (8,433) $ (15,597)